D. Basire

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Paul J. Harrison, Gary F. Simons, A. L. Tan, 2023, The Lancet Regional Health - Europe.

Anti-inflammatory therapy with nebulised dornase alfa in patients with severe COVID-19 pneumonia

V. Johnston, H. Esmail, R. Evans, 2022, medRxiv.

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

Gary F. Simons, A. L. Tan, L. Wain, 2023, eClinicalMedicine.

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Paul J. Harrison, Gary F. Simons, A. L. Tan, 2023, The Lancet Respiratory Medicine.

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

Paul J. Harrison, Jennifer M. Brown, Gary F. Simons, 2022, The Lancet. Respiratory medicine.

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Panteleimon G. Takis, Jordan J. Clark, Michael J. Murphy, 2022, eBioMedicine.

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Thomas E. Nichols, Paul J. Harrison, Jennifer M. Brown, 2023, The Lancet. Respiratory medicine.

Accelerated immune ageing is associated with COVID-19 disease severity

M. G. Jones, M. Halling-Brown, K. Motohashi, 2024, Immunity & Ageing.

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

H. Esmail, E. Helbig, A. Last, 2024, eLife.